Literature DB >> 33112806

Phosphodiesterase 2A and 3B variants are associated with primary aldosteronism.

Marcela Rassi-Cruz1, Andrea G Maria2, Fabio R Faucz2, Edra London2, Leticia A P Vilela1, Lucas S Santana1, Anna Flavia F Benedetti1, Tatiana S Goldbaum1, Fabio Y Tanno3, Vitor Srougi3, Jose L Chambo3, Maria Adelaide A Pereira1, Aline C B S Cavalcante4, Francisco C Carnevale4, Bruna Pilan4, Luiz A Bortolotto5, Luciano F Drager5,6, Antonio M Lerario1,7, Ana Claudia Latronico1, Maria Candida B V Fragoso1,8, Berenice B Mendonca1, Maria Claudia N Zerbini9, Constantine A Stratakis2, Madson Q Almeida1,8.   

Abstract

Familial primary aldosteronism (PA) is rare and mostly diagnosed in early-onset hypertension (HT). However, 'sporadic' bilateral adrenal hyperplasia (BAH) is the most frequent cause of PA and remains without genetic etiology in most cases. Our aim was to investigate new genetic defects associated with BAH and PA. We performed whole-exome sequencing (paired blood and adrenal tissue) in six patients with PA caused by BAH that underwent unilateral adrenalectomy. Additionally, we conducted functional studies in adrenal hyperplastic tissue and transfected cells to confirm the pathogenicity of the identified genetic variants. Rare germline variants in phosphodiesterase 2A (PDE2A) and 3B (PDE3B) genes were identified in three patients. The PDE2A heterozygous variant (p.Ile629Val) was identified in a patient with BAH and early-onset HT at 13 years of age. Two PDE3B heterozygous variants (p.Arg217Gln and p.Gly392Val) were identified in patients with BAH and HT diagnosed at 18 and 33 years of age, respectively. A strong PDE2A staining was found in all cases of BAH in zona glomerulosa and/or micronodules (that were also positive for CYP11B2). PKA activity in frozen tissue was significantly higher in BAH from patients harboring PDE2A and PDE3B variants. PDE2A and PDE3B variants significantly reduced protein expression in mutant transfected cells compared to WT. Interestingly, PDE2A and PDE3B variants increased SGK1 and SCNN1G/ENaCg at mRNA or protein levels. In conclusion, PDE2A and PDE3B variants were associated with PA caused by BAH. These novel genetic findings expand the spectrum of genetic etiologies of PA.

Entities:  

Keywords:  adrenal hyperplasia; phosphodiesterases; primary aldosteronism

Mesh:

Substances:

Year:  2021        PMID: 33112806      PMCID: PMC7757641          DOI: 10.1530/ERC-20-0384

Source DB:  PubMed          Journal:  Endocr Relat Cancer        ISSN: 1351-0088            Impact factor:   5.678


  60 in total

1.  Hypertension with or without adrenal hyperplasia due to different inherited mutations in the potassium channel KCNJ5.

Authors:  Ute I Scholl; Carol Nelson-Williams; Peng Yue; Roger Grekin; Robert J Wyatt; Michael J Dillon; Robert Couch; Lisa K Hammer; Frances L Harley; Anita Farhi; Wen-Hui Wang; Richard P Lifton
Journal:  Proc Natl Acad Sci U S A       Date:  2012-01-30       Impact factor: 11.205

2.  Exomic variants of an elderly cohort of Brazilians in the ABraOM database.

Authors:  Michel Satya Naslavsky; Guilherme Lopes Yamamoto; Tatiana Ferreira de Almeida; Suzana A M Ezquina; Daniele Yumi Sunaga; Nam Pho; Daniel Bozoklian; Tatiana Orli Milkewitz Sandberg; Luciano Abreu Brito; Monize Lazar; Danilo Vicensotto Bernardo; Edson Amaro; Yeda A O Duarte; Maria Lúcia Lebrão; Maria Rita Passos-Bueno; Mayana Zatz
Journal:  Hum Mutat       Date:  2017-05-03       Impact factor: 4.878

3.  EMD638683, a novel SGK inhibitor with antihypertensive potency.

Authors:  Teresa F Ackermann; Krishna M Boini; Norbert Beier; Wolfgang Scholz; Thomas Fuchss; Florian Lang
Journal:  Cell Physiol Biochem       Date:  2011-08-16

4.  Cellular and Genetic Causes of Idiopathic Hyperaldosteronism.

Authors:  Kei Omata; Fumitoshi Satoh; Ryo Morimoto; Sadayoshi Ito; Yuto Yamazaki; Yasuhiro Nakamura; Sharath K Anand; Zeng Guo; Michael Stowasser; Hironobu Sasano; Scott A Tomlins; William E Rainey
Journal:  Hypertension       Date:  2018-10       Impact factor: 10.190

5.  Cyclic AMP and c-KIT signaling in familial testicular germ cell tumor predisposition.

Authors:  Monalisa F Azevedo; Anelia Horvath; Ethan R Bornstein; Madson Q Almeida; Paraskevi Xekouki; Fabio R Faucz; Evgenia Gourgari; Kiran Nadella; Elaine F Remmers; Martha Quezado; Rodrigo Bertollo de Alexandre; Christian P Kratz; Maria Nesterova; Mark H Greene; Constantine A Stratakis
Journal:  J Clin Endocrinol Metab       Date:  2013-06-14       Impact factor: 5.958

6.  Examination of chromosome 7p22 candidate genes RBaK, PMS2 and GNA12 in familial hyperaldosteronism type II.

Authors:  Y W A Jeske; A So; L Kelemen; N Sukor; C Willys; B Bulmer; R D Gordon; D Duffy; M Stowasser
Journal:  Clin Exp Pharmacol Physiol       Date:  2008-04       Impact factor: 2.557

7.  Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology.

Authors:  Sue Richards; Nazneen Aziz; Sherri Bale; David Bick; Soma Das; Julie Gastier-Foster; Wayne W Grody; Madhuri Hegde; Elaine Lyon; Elaine Spector; Karl Voelkerding; Heidi L Rehm
Journal:  Genet Med       Date:  2015-03-05       Impact factor: 8.822

8.  A global reference for human genetic variation.

Authors:  Adam Auton; Lisa D Brooks; Richard M Durbin; Erik P Garrison; Hyun Min Kang; Jan O Korbel; Jonathan L Marchini; Shane McCarthy; Gil A McVean; Gonçalo R Abecasis
Journal:  Nature       Date:  2015-10-01       Impact factor: 49.962

9.  Steroid metabolome analysis reveals prevalent glucocorticoid excess in primary aldosteronism.

Authors:  Wiebke Arlt; Katharina Lang; Alice J Sitch; Anna S Dietz; Yara Rhayem; Irina Bancos; Annette Feuchtinger; Vasileios Chortis; Lorna C Gilligan; Philippe Ludwig; Anna Riester; Evelyn Asbach; Beverly A Hughes; Donna M O'Neil; Martin Bidlingmaier; Jeremy W Tomlinson; Zaki K Hassan-Smith; D Aled Rees; Christian Adolf; Stefanie Hahner; Marcus Quinkler; Tanja Dekkers; Jaap Deinum; Michael Biehl; Brian G Keevil; Cedric Hl Shackleton; Jonathan J Deeks; Axel K Walch; Felix Beuschlein; Martin Reincke
Journal:  JCI Insight       Date:  2017-04-20

Review 10.  Aldosterone, SGK1, and ion channels in the kidney.

Authors:  William C Valinsky; Rhian M Touyz; Alvin Shrier
Journal:  Clin Sci (Lond)       Date:  2018-01-19       Impact factor: 6.124

View more
  8 in total

Review 1.  What Did We Learn from the Molecular Biology of Adrenal Cortical Neoplasia? From Histopathology to Translational Genomics.

Authors:  C Christofer Juhlin; Ozgur Mete; Jérôme Bertherat; Thomas J Giordano; Gary D Hammer; Hironobu Sasano
Journal:  Endocr Pathol       Date:  2021-02-03       Impact factor: 3.943

Review 2.  Pathophysiology of bilateral hyperaldosteronism.

Authors:  Kazutaka Nanba; William E Rainey
Journal:  Curr Opin Endocrinol Diabetes Obes       Date:  2022-06-01       Impact factor: 3.626

Review 3.  Pathogenesis of Primary Aldosteronism: Impact on Clinical Outcome.

Authors:  Lucas S Santana; Augusto G Guimaraes; Madson Q Almeida
Journal:  Front Endocrinol (Lausanne)       Date:  2022-06-23       Impact factor: 6.055

Review 4.  Genetic Alterations in Benign Adrenal Tumors.

Authors:  Georgia Pitsava; Constantine A Stratakis
Journal:  Biomedicines       Date:  2022-04-30

Review 5.  Molecular Genetic and Genomic Alterations in Cushing's Syndrome and Primary Aldosteronism.

Authors:  Crystal D C Kamilaris; Constantine A Stratakis; Fady Hannah-Shmouni
Journal:  Front Endocrinol (Lausanne)       Date:  2021-03-12       Impact factor: 5.555

Review 6.  Update on Genetics of Primary Aldosteronism.

Authors:  Kiyotaka Itcho; Kenji Oki; Haruya Ohno; Masayasu Yoneda
Journal:  Biomedicines       Date:  2021-04-10

Review 7.  Genetics of Primary Aldosteronism.

Authors:  Ute I Scholl
Journal:  Hypertension       Date:  2022-02-10       Impact factor: 10.190

Review 8.  Disorders of the adrenal cortex: Genetic and molecular aspects.

Authors:  Georgia Pitsava; Andrea G Maria; Fabio R Faucz
Journal:  Front Endocrinol (Lausanne)       Date:  2022-08-29       Impact factor: 6.055

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.